U.S. FDA Grants Regular Approval and Expands Indication for Padcev (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
Regular Approval Based on Overall Survival Results from Confirmatory EV-301 Trial First and Only FDA-Approved...
